A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies.
The study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a Post-Treatment Follow-Up Phase.
Participants will receive their assigned dose of PLX-61639 administered orally, once daily until progression/relapse, intolerance, death, or withdrawal from study treatment by the Investigator or participant.
Participants with locally advanced or metastatic, relapsed/refractory, solid tumors harboring a SMARCA4 loss-of-function mutation that have progressed on, are intolerant of, or not otherwise candidates for available approved therapies
Adequate liver bone marrow, coagulation, renal, and cardiopulmonary function
Measurable disease per RECIST 1.1
ECOG PS of 0 or 1
Germline SMARCA4 mutations
Known SMARCA2 mutation or loss of expression
Symptomatic CNS disease
Prior treatment with another SMARCA2-directed therapy
Sequential
PLX-61639
DrugOrally available degrader of SMARCA2
Treatment Emergent Adverse Events
Dose-Limiting Toxicities
Dose reductions due to Adverse Events
Study treatment discontinuations for reasons other than disease progression
Pharmacokinetics of PLX-61639: Cmax
Pharmacokinetics of PLX-61639: Tmax
Click on the lead sponsor to view all of their trials.
